Online Database of Chemicals from Around the World

乙琥胺
[CAS# 77-67-8]

供应商
Alfa Chemistry 美国 询价快递  
+1 (201) 478-8534
inquiry@alfa-chemistry.com
化学品供销商(2012 年起)
chemBlink 标准供应商(2012 年起)
Alsachim SAS 法国 询价快递  
+33 (368) 240-080
contact@alsachim.com
化学品生产商
Biosynth AG. 瑞士 询价快递  
+41 (71) 858-2020
welcome@biosynth.ch
化学品生产商
CacheSyn Inc. 加拿大 询价快递  
+1 (416) 996-8186
info@cachesyn.com
化学品生产商
Glentham Life Sciences 英国 询价快递  
+44 (2033) 978-798
info@glenthamls.com
化学品供销商(2013 年起)
International Laboratory Limited 美国 询价快递  
+1 (650) 278-9963
admin@intlab.org
化学品生产商(2002 年起)
LGC Standards 英国 询价快递  
+44 (20) 8943-8480
uksales@lgcstandards.com
化学品生产商(2007 年起)
RIA International LLC 美国 询价快递  
+1 (973) 581-1282/
marketing@riausa.net,nj@riausa.net
化学品供销商
Santa Cruz Biotechnology, Inc. 美国 询价快递  
+1 (831) 457-3800
scbt@scbt.com
化学品生产商
TimTec 美国 询价快递  
+1 (302) 292-8500
info@timtec.com
化学品生产商
基本信息
产品分类 原料药 >> 神经系统用药 >> 抗癫痫及抗惊厥药
产品名称 乙琥胺
英文名 Ethosuximide
别名 3-Ethyl-3-Methyl-Pyrrolidine-2,5-Dione; 3-Ethyl-3-Methyl-Pyrrolidine-2,5-Quinone; Spectrum4_001051
分子结构 CAS 登录号:77-67-8, 乙琥胺
分子式 C7H11NO2
分子量 141.17
CAS 登录号 77-67-8
EINECS 登录号 201-048-7
分子行输入简码 SMILES C(C1(C(NC(C1)=O)=O)C)C
国际化学标识码 InChI 1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
国际化学标识检索码 InChIKey HAPOVYFOVVWLRS-UHFFFAOYSA-N
物理化学性质
密度 1.1±0.1g/cm3 (计算值)
熔点 51°C (实验值)
沸点 265.3±9.0°C at 760 mmHg (计算值)
闪点 123.8±18.9°C (计算值)
安全数据
SDS 化学品安全技术说明书参考文本
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
市场分析报告
请浏览乙琥胺市场分析报告总目录
相关产品
(3-碘-131I-苄基)胍  N-[2-(3-乙烯基苯基)乙基]丙-2-胺  1,3,3,5,5-五氮丙啶基-1-硫杂-2,4,...  5,5-二甲基-2-苯基-1,3-二恶烷  2-(4-氨基-5H-吡咯并[5,4-e]嘧啶-7...  3-(苄基氨基)-5,5-二甲基四氢呋喃-2-酮盐...  N-(5,5-二甲基-2-氧代四氢呋喃-3-基)乙...  N-(5,5-二甲基-2-氧代四氢呋喃-3-基)-...  (E)-N-(5,5-二甲基-2-氧代四氢呋喃-3...  1-(5,5-二甲基-2-氧代四氢呋喃-3-基)-...  4-氯-N-(5,5-二甲基-2-氧代四氢呋喃-3...  3-氯-N-(5,5-二甲基-2-氧代四氢呋喃-3...  2-氯-N-(5,5-二甲基-2-氧代四氢呋喃-3...  N-(5,5-二甲基-2-氧代四氢呋喃-3-基)-...  N-(5,5-二甲基-2-氧代四氢呋喃-3-基)-...